Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has rolled out its roadmap for the next 18 months, which builds on the significant clinical progress made to date.
An early milestone comes from the release of full cohort data for SCIB1 and iSCIB1+ (for melanoma) in late 2024 and early 2025.
The cancer immunotherapy specialist also plans to launch a phase II/III registration trial for SCIB1 or iSCIB1+ in 2025.
In the first stage of the phase II study of SCIB1, 11 out of 13 patients achieved at least a partial response, exceeding the 70% overall response rate the trial was configured to show.
Additionally, data from the ModiFY study in renal cell carcinoma (RCC), using Modi-1 in combination with checkpoint inhibitors, is expected in the first half of 2025.
The company is also focused on exploring partnering or out-licensing opportunities for its GlyMab and AvidiMab platforms.
The update was provided alongside results for the 12 months ended April 30, which showed the group posted a loss of £18.3 million after investing heavily in its drug R&D effort.
More importantly, it exited the period with £14.8 million on the balance sheet - providing a cash runway out to the third quarter of next year.
"Given the significant clinical and commercial milestones achieved in the period, positive early efficacy data, and sufficient resources to fund the current strategy, the company is confident it will achieve its near-term milestones," said CEO, Professor Lindy Durrant.